Johnson & Johnson announced that it had achieved positive results in a phase 3 study using INVOKANA along with standard of care to treat type 2 diabetes patients.

The most notable finding from the study is that INVOKANA was shown to be able to reduce the risk of end-stage kidney disease for these type 2 diabetes patients by 32%.

The company has already submitted its sNDA for INVOKANA to treat patients with type 2 diabetes who have kidney disease.

READ FULL ARTICLE HERE